Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LY2409021 in Type 2 Diabetes
NCT01241448Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jan 2011
- Primary completion
- Feb 2012
- Modality
- Small Molecules
- Countries
- 7
01
Overview
A Phase 2 trial of adomeglivant in type 2 diabetes mellitus (T2DM), sponsored by Eli Lilly and Company. Started Jan 2011; status: completed.
02
Drugs
adomeglivant
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT01241448.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01241448.